GSK2256294A
GSK2256294A (GSK 2256294) is a selective and orally active inhibitor of soluble epoxide hydrolase (sEH) . GSK2256294A inhibits recombinant human sEH, rat sEH orthologs and murine sEH orthologs with IC50s of 27, 61 and 189 pM, respectively. GSK2256294A can be used for the research of chronic obstructive pulmonary disease (COPD) and cardiovascular disease[1].
Product Specifications
CAS Number
1142090-23-0
Product Name Alternative
GSK 2256294
UNSPSC
12352005
Target
Epoxide Hydrolase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/GSK2256294A.html
Concentration
10mM
Purity
99.84
Solubility
DMSO : ≥ 47 mg/mL
Smiles
O=C([C@H]1C[C@@H](NC2=NC(NC)=NC(C)=N2)CCC1)NCC3=CC=C(C#N)C=C3C(F)(F)F
Molecular Formula
C21H24F3N7O
Molecular Weight
447.46
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
TGF-beta (1D11.16.8), CF568 conjugate, 0.1mg/mL
CD106 / VCAM1 (1.4C3), CF647 conjugate, 0.1mg/mL
Ep-CAM / CD326 (Epithelial Marker) (rVU-1D9), CF594 conjugate, 0.1mg/mL
Complement C4d (C4D204), CF405S conjugate, 0.1mg/mL
